Covestro Valuation

Is 1COV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1COV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1COV (€50.24) is trading below our estimate of fair value (€100.65)

Significantly Below Fair Value: 1COV is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1COV?

Other financial metrics that can be useful for relative valuation.

1COV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA15.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 1COV's PS Ratio compare to its peers?

The above table shows the PS ratio for 1COV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.3x
EVK Evonik Industries
0.6x2.0%€8.6b
SY1 Symrise
3.2x5.8%€15.3b
WCH Wacker Chemie
0.8x2.7%€5.4b
ACT AlzChem Group
0.7x3.8%€376.5m
1COV Covestro
0.7x3.9%€9.5b

Price-To-Sales vs Peers: 1COV is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (1.3x).


Price to Earnings Ratio vs Industry

How does 1COV's PE Ratio compare vs other companies in the European Chemicals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a32.0%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a32.0%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 1COV is good value based on its Price-To-Sales Ratio (0.7x) compared to the European Chemicals industry average (1x).


Price to Sales Ratio vs Fair Ratio

What is 1COV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1COV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.7x
Fair PS Ratio0.4x

Price-To-Sales vs Fair Ratio: 1COV is expensive based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1COV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€50.24
€53.14
+5.8%
13.4%€61.00€38.00n/a14
Mar ’25€50.42
€53.29
+5.7%
13.3%€61.00€38.00n/a14
Feb ’25€47.75
€52.80
+10.6%
13.2%€61.00€38.00n/a15
Jan ’25€52.68
€53.73
+2.0%
13.6%€66.00€38.00n/a15
Dec ’24€51.00
€53.73
+5.4%
13.6%€66.00€38.00n/a15
Nov ’24€47.55
€53.93
+13.4%
13.4%€66.00€38.00n/a15
Oct ’24€51.06
€54.13
+6.0%
13.7%€66.00€38.00n/a15
Sep ’24€48.98
€52.35
+6.9%
14.5%€66.00€38.00n/a17
Aug ’24€48.39
€49.24
+1.7%
15.6%€66.00€38.00n/a17
Jul ’24€47.58
€48.25
+1.4%
15.5%€66.00€38.00n/a18
Jun ’24€36.35
€46.18
+27.1%
14.7%€65.00€34.00n/a19
May ’24€39.79
€45.34
+14.0%
15.5%€65.00€34.00n/a19
Apr ’24€38.13
€44.29
+16.2%
17.4%€64.00€33.00n/a19
Mar ’24€41.46
€42.79
+3.2%
15.7%€60.00€33.00€50.4219
Feb ’24€42.56
€42.37
-0.5%
14.6%€56.00€33.00€47.7519
Jan ’24€36.55
€41.53
+13.6%
15.0%€56.00€31.00€52.6819
Dec ’23€37.17
€41.26
+11.0%
15.0%€56.00€31.00€51.0019
Nov ’23€33.93
€41.79
+23.2%
14.9%€57.00€31.00€47.5519
Oct ’23€29.54
€42.63
+44.3%
16.8%€57.00€31.00€51.0619
Sep ’23€29.58
€43.16
+45.9%
15.4%€57.00€32.00€48.9819
Aug ’23€33.05
€49.79
+50.6%
22.6%€79.00€32.00€48.3919
Jul ’23€32.53
€54.18
+66.6%
18.4%€78.00€32.00€47.5819
Jun ’23€43.08
€56.33
+30.7%
18.0%€79.00€38.00€36.3520
May ’23€41.29
€60.75
+47.1%
17.1%€80.00€38.00€39.7920
Apr ’23€45.66
€63.60
+39.3%
15.0%€80.00€43.00€38.1320
Mar ’23€46.13
€65.60
+42.2%
14.1%€89.00€52.00€41.4620

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.